About A&A Biotechnology
A&A Biotechnology is a Healthcare company based in Gdansk (Poland) founded in 1993 by Adam Burkiewicz and Amanda Hall-Frasure. Its chief executive is Adam Burkiewicz. A&A Biotechnology offers products and services including MagnifiQâ„¢ automatic isolation, DNA purification, RNA purification, PCR and reverse transcription, and Enzymes. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Genomics. Its competitors include ArcherDX, Qiagen, Devyser, DxTerity and PredictImmune and 5 more; 5 of its 10 listed competitors have raised funding.
Company details
Provider of genomic-based products for the life science industry. It offers offer includes DNA and RNA isolation kits, PCR and reverse transcription reagents, cloning and transformation reagents, molecular biology reagents and services.
- Headquarters Gdansk, Poland
- Founders Adam Burkiewicz, Amanda Hall-Frasure
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website aabiot.com
- Social LinkedIn Facebook YouTube
- Latest Funding Round$367.39K (USD), Grant
Apr 2016
- Investors
Products & Services of A&A Biotechnology
A&A Biotechnology offers a comprehensive portfolio of products and services, including MagnifiQ™ automatic isolation, DNA purification, RNA purification, PCR and reverse transcription, and Enzymes.
System for automatic isolation in molecular biology applications
Kits for purifying DNA from various samples
Tools for RNA extraction and purification processes
Reagents for polymerase chain reaction and transcription
Various enzymes for molecular and protein research
Apps and channels of A&A Biotechnology
its YouTube channel A&A Biotechnology has 27 subscribers and 5 videos.
Videos from A&A Biotechnology
The most watched videos on A&A Biotechnology's YouTube channel, A&A Biotechnology (27 subscribers). Click a video to play it here.
More on A&A Biotechnology.
Funding Insights of A&A Biotechnology
- Total Rounds 2
- Last Round Grant — $367,386
- First Round $349,042
(Jan 2016)
- Investors Count 1
All 2 funding rounds of AA Biotechnology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2016 | $367,386 | Grant | – | – | |
| Jan 2016 | $349,042 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in A&A Biotechnology
A&A Biotechnology has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for AA Biotechnology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of A&A Biotechnology
2 people are tracked at A&A Biotechnology (2 in leadership).
| Name | Role | Group |
|---|---|---|
Adam Burkiewicz | Co-Founder & CEO | Leadership |
Amanda Hall-Frasure | Co-Founder | Leadership |
Complete people profiles for A&A Biotechnology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of A&A Biotechnology
3 dated milestones of A&A Biotechnology across 23 years, from founding to its latest funding, stage changes and deals.
- Founded A&A Biotechnology is founded.
- Funding First funding round of $349K.
- Funding Latest funding round, Grant, of $367K.
Competitors of A&A Biotechnology
A&A Biotechnology has 10 listed competitors in our database, 5 of them funded. They include ArcherDX, Qiagen, Devyser, DxTerity and PredictImmune, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| qiagen.com | 1984 | Hilden, Germany | – | 104 | Products and reagents for molecular diagnostic assays are supplied. | |
| devyser.com | 2004 | Stockholm, Sweden | $15.48M | – | Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders | |
| dxterity.com | 2006 | Los Angeles, United States | $3.75M | – | Provider of a direct-to-consumer, non-clinical genetic tests | |
| predictimmune.com | 2017 | Cambridge, United Kingdom | $18.32M | 15 | Tools for diagnosing immune-mediated inflammatory diseases are developed. | |
| biogene.com | 1993 | Peterborough, United Kingdom | – | 6 | Manufacturer of specialist molecular biology analytical instruments and reagents | |
| ampedpcr.co.uk | 2020 | Aberystwyth, United Kingdom | $444,423 | – | Molecular diagnostic solutions are developed for research and diagnostic labs. | |
| 4saliva.com | 2002 | Vancouver, United States | – | – | Non-invasive saliva-based diagnostics and collection tools are developed and marketed. | |
| fluorogenics.co.uk | 2011 | Salisbury, United Kingdom | – | 8 | Lyophilized reagents for stable nucleic acid amplification are supplied. | |
| raslifesciences.com | 2008 | Hyderabad, India | – | 289 | Assays on PCR and Real Time PCR technologies for diagnosis and monitoring diseases |
Detailed competitors of AA Biotechnology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of A&A Biotechnology
The website of A&A Biotechnology (aabiot.com) receives about 7.1K visits a month.
- Monthly visits7.1K
▲ 133.9% vs previous month
Websites whose visitors overlap most with A&A Biotechnology. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
recenttec.co.jp | recenttec.co.jp | 100% | – | #4,836,525 | – |
| polpharmabiologics.com | 98% | – | #2,814,664 | View details | |
abo.com.pl | abo.com.pl | 95% | – | #2,390,732 | – |
feminature.pl | feminature.pl | 85% | – | #5,097,354 | – |
| genomed.pl | 82% | 8.8K | #1,853,263 | View details |
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as A&A Biotechnology (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about A&A Biotechnology
A&A Biotechnology was founded in 1993 and raised its 1st funding round 23 years after it was founded.
A&A Biotechnology is headquartered in Gdansk, Poland. It is registered at Gdansk, Pomeranian Voivodeship, Poland.
Adam Burkiewicz is the current CEO of A&A Biotechnology. They have also founded this company.
Provider of genomic-based products for the life science industry. It offers offer includes DNA and RNA isolation kits, PCR and reverse transcription reagents, cloning and transformation reagents, molecular biology reagents and services.
A&A Biotechnology offers MagnifiQâ„¢ automatic isolation, DNA purification, RNA purification, PCR and reverse transcription, and Enzymes.
A&A Biotechnology has 1 investor. Key investors include European Union.